Shares in CSL Limited (ASX:CSL) have risen after improving its profit over the 2014 financial year and forecasting profit growth in the year ahead.
The biopharmaceutical products manufacturer’s net profit lifted 7.8 per cent to $US1.3 billion. Sales of immunoglobulin products gained 12 per cent while revenue rose 7.7 per cent to $US5.3 billion.
CEO Paul Perreault says the company continues to see robust global demand for plasma therapies and the company is strongly positioned in a competitive market.
Over the coming year CSL expects its net profit to grow by about 12 per cent and earnings to rise by about 15 per cent at constant currency.
CSL has also revealed it is considering another on-market share buyback of a similar amount to the current program of $950 million.
An unfranked final dividend of $US0.60 per share has been declared.
